BCMA CAR-NK (Shenzhen Pregene Biopharma) vs Trovocabtagene autoleucel (C-CAR088)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

BCMA CAR-NK (Shenzhen Pregene Biopharma)

Developed by Shenzhen Pregene Biopharma Co., Ltd.

Phase 1/2 in Multiple Myelomaallogeneic CAR-NK cell therapy
Weak signal

NCT05652530 · Phase 1 · status unknown

This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 19 participants, and it measured only safety. Results have not been posted yet.

No aligned efficacy figure on record for this race.

Trovocabtagene autoleucel (C-CAR088)

Developed by AbelZeta Pharma, Inc.

Phase 1/2 in Multiple MyelomaCAR-T cell therapy
Weak signal

NCT03751293 · Phase 1 · status unknown

This is a very small, open-label, single-arm safety study of a cell therapy with no comparator group and no blinding, and results have not yet been posted.

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBCMA CAR-NK (Shenzhen Pregene Biopharma)Trovocabtagene autoleucel (C-CAR088)
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
VGPR or better—Not reported—Not reported
MRD negativity—Not reported—Not reported

PFS, median

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
Trovocabtagene autoleucel (C-CAR088)
—Not reported

OS, median

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
Trovocabtagene autoleucel (C-CAR088)
—Not reported

ORR

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
Trovocabtagene autoleucel (C-CAR088)
—Not reported

VGPR or better

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
Trovocabtagene autoleucel (C-CAR088)
—Not reported

MRD negativity

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
Trovocabtagene autoleucel (C-CAR088)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

BCMA CAR-NK (Shenzhen Pregene Biopharma): no structured comparison results are available for Multiple Myeloma.

Trovocabtagene autoleucel (C-CAR088): no structured comparison results are available for Multiple Myeloma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCMA CAR-NK (Shenzhen Pregene Biopharma)'s landscape · Trovocabtagene autoleucel (C-CAR088)'s landscape